These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16705058)

  • 1. Parenteral and enteral metabolism of anaplerotic triheptanoin in normal rats.
    Kinman RP; Kasumov T; Jobbins KA; Thomas KR; Adams JE; Brunengraber LN; Kutz G; Brewer WU; Roe CR; Brunengraber H
    Am J Physiol Endocrinol Metab; 2006 Oct; 291(4):E860-6. PubMed ID: 16705058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parenteral and enteral metabolism of anaplerotic triheptanoin in normal rats. II. Effects on lipolysis, glucose production, and liver acyl-CoA profile.
    Gu L; Zhang GF; Kombu RS; Allen F; Kutz G; Brewer WU; Roe CR; Brunengraber H
    Am J Physiol Endocrinol Metab; 2010 Feb; 298(2):E362-71. PubMed ID: 19903863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac tissue citric acid cycle intermediates in exercised very long-chain acyl-CoA dehydrogenase-deficient mice fed triheptanoin or medium-chain triglyceride.
    Gaston G; Gangoiti JA; Winn S; Chan B; Barshop BA; Harding CO; Gillingham MB
    J Inherit Metab Dis; 2020 Nov; 43(6):1232-1242. PubMed ID: 33448436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Pharmacokinetics of Triheptanoin and Its Metabolites in Healthy Subjects and Patients With Long-Chain Fatty Acid Oxidation Disorders.
    Lee SK; Gupta M; Shi J; McKeever K
    Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1325-1334. PubMed ID: 33789001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride.
    Roe CR; Sweetman L; Roe DS; David F; Brunengraber H
    J Clin Invest; 2002 Jul; 110(2):259-69. PubMed ID: 12122118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyruvate carboxylase deficiency: clinical and biochemical response to anaplerotic diet therapy.
    Mochel F; DeLonlay P; Touati G; Brunengraber H; Kinman RP; Rabier D; Roe CR; Saudubray JM
    Mol Genet Metab; 2005 Apr; 84(4):305-12. PubMed ID: 15781190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triheptanoin: long-term effects in the very long-chain acyl-CoA dehydrogenase-deficient mouse.
    Tucci S; Floegel U; Beermann F; Behringer S; Spiekerkoetter U
    J Lipid Res; 2017 Jan; 58(1):196-207. PubMed ID: 27884962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of impaired ketogenesis in fatty acid oxidation disorders.
    Olpin SE
    Prostaglandins Leukot Essent Fatty Acids; 2004 Mar; 70(3):293-308. PubMed ID: 14769488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetics of Heptanoate in Healthy Subjects and Patients With Long-Chain Fatty Acid Oxidation Disorders Treated With Triheptanoin.
    Lee SK; Gosselin NH; Jomphe C; McKeever K; Putnam W
    Clin Pharmacol Drug Dev; 2022 Nov; 11(11):1264-1272. PubMed ID: 35908210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triheptanoin: First Approval.
    Shirley M
    Drugs; 2020 Oct; 80(15):1595-1600. PubMed ID: 32897506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced severity of ischemic stroke and improvement of mitochondrial function after dietary treatment with the anaplerotic substance triheptanoin.
    Schwarzkopf TM; Koch K; Klein J
    Neuroscience; 2015 Aug; 300():201-9. PubMed ID: 25982559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triheptanoin--a medium chain triglyceride with odd chain fatty acids: a new anaplerotic anticonvulsant treatment?
    Borges K; Sonnewald U
    Epilepsy Res; 2012 Jul; 100(3):239-44. PubMed ID: 21855298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaplerotic treatment of long-chain fat oxidation disorders with triheptanoin: Review of 15 years Experience.
    Roe CR; Brunengraber H
    Mol Genet Metab; 2015 Dec; 116(4):260-8. PubMed ID: 26547562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heptanoate is neuroprotective in vitro but triheptanoin post-treatment did not protect against middle cerebral artery occlusion in rats.
    Tan KN; Hood R; Warren K; Pepperall D; Carrasco-Pozo C; Manzanero S; Borges K; Spratt NJ
    Neurosci Lett; 2018 Sep; 683():207-214. PubMed ID: 30076987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interrelations between C4 ketogenesis, C5 ketogenesis, and anaplerosis in the perfused rat liver.
    Deng S; Zhang GF; Kasumov T; Roe CR; Brunengraber H
    J Biol Chem; 2009 Oct; 284(41):27799-27807. PubMed ID: 19666922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The hypertriglyceridemic clamp technique. Studies using long-chain and structured triglyceride emulsions in healthy subjects.
    Nordenström J; Thörne A; Aberg W; Carneheim C; Olivecrona T
    Metabolism; 2006 Nov; 55(11):1443-50. PubMed ID: 17046545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tutorial: Triheptanoin and Nutrition Management for Treatment of Long-Chain Fatty Acid Oxidation Disorders.
    Norris MK; Scott AI; Sullivan S; Chang IJ; Lam C; Sun A; Hahn S; Thies JM; Gunnarson M; McKean KN; Merritt JL
    JPEN J Parenter Enteral Nutr; 2021 Feb; 45(2):230-238. PubMed ID: 33085788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment--A retrospective chart review.
    Vockley J; Marsden D; McCracken E; DeWard S; Barone A; Hsu K; Kakkis E
    Mol Genet Metab; 2015; 116(1-2):53-60. PubMed ID: 26116311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triheptanoin reduces seizure susceptibility in a syndrome-specific mouse model of generalized epilepsy.
    Kim TH; Borges K; Petrou S; Reid CA
    Epilepsy Res; 2013 Jan; 103(1):101-5. PubMed ID: 23196212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triheptanoin treatment in patients with pediatric cardiomyopathy associated with long chain-fatty acid oxidation disorders.
    Vockley J; Charrow J; Ganesh J; Eswara M; Diaz GA; McCracken E; Conway R; Enns GM; Starr J; Wang R; Abdenur JE; Sanchez-de-Toledo J; Marsden DL
    Mol Genet Metab; 2016 Nov; 119(3):223-231. PubMed ID: 27590926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.